https://journals.aboutscience.eu/index.php/jcb/issue/feedJournal of Circulating Biomarkers2024-06-26T11:52:54+00:00Lucia Steelelucia.steele@aboutscience.euOpen Journal Systems<p><strong>Journal of Circulating Biomarkers</strong> is an international, peer-reviewed, open access scientific journal focusing on all aspects of the rapidly growing field of circulating blood-based biomarkers and diagnostics using circulating protein and lipid markers, circulating tumor cells (CTC), circulating cell-free DNA (cfDNA) and extracellular vesicles, including exosomes, microvesicles, microparticles, ectosomes and apoptotic bodies.<br><br></p>https://journals.aboutscience.eu/index.php/jcb/article/view/2689Relation between interleukin-13 and annexin-V levels and carotid intima-media thickness in nephrotic syndrome2024-06-18T14:03:32+00:00Asmaa Elsehmawyasmaawakeel@yahoo.comRasha Mahmoud GoudaRashagoda6@gmail.comFatma Elzhraa Ahmed Diabdr_fatma.diab@yahoo.comOla Ismail SalehOlaismailrad@gmail.comHeba Mohamed GalalHebaglal7@gmil.comMona Gamal El Din Al AnanyMonagamal403@gmail.comSalwa Samir Abd ElgwadDr.salwasamir2017@gmail.comMarwa Mohsen Hassanmarwamohsen83@yahoo.comMohamed Ahmed Mostafa Kamal AhmedDr.Mohamedmakamal@yahoo.comAhmed Yousri Elamirangellook2@yahoo.com<p class="abstract"><strong>Background and aim:</strong> The aim of the current study is to assess the relation between carotid intima-media thickness (CIMT) measurements, renal Doppler resistive index (RI) and serum levels of interleukin-13 (IL-13) and annexin-V (An-V) in children with idiopathic nephrotic syndrome (INS).</p> <p class="abstract"><strong>Materials and methods:</strong> The present case-control study was conducted on 60 children with INS and 60 age- and sex-matched healthy children. All participants were subjected to evaluation of serum levels of IL-13 and An-V and ultrasound Doppler measurement of CIMT and renal RI.</p> <p class="abstract"><strong>Results:</strong> Patients expressed significantly higher An-V (5.9 ± 2.6 vs. 2.1 ± 0.8 ng/mL, p<0.001) and IL-13 (19.2 ± 7.6 vs. 3.4 ± 1.4 ng/L) levels when compared with healthy counterparts. Moreover, it was shown that patients had significantly higher CIMT (0.49 ± 0.06 vs. 0.35 ± 0.03, p<0.001) as compared to controls. No significant differences were noted between the studied groups regarding right or left RIs. Correlation analysis identified significant direct correlation between serum An-V levels and albumin/creatinine ratio (ACR) (r = 0.55), cholesterol (r = 0.48), triglycerides (r = 0.36), IL-13 (r = 0.92) and CIMT (r = 0.53). Similar correlations could be found between serum IL-13 levels and CIMT measurements and the corresponding parameters.</p> <p class="abstract"><strong>Conclusions:</strong> The present study suggests an association between higher early atherosclerosis expressed as elevated CIMT measurements in children with INS and elevated serum levels of An-V and IL-13.</p>2024-06-18T00:00:00+00:00Copyright (c) 2024 Asmaa Elsehmawy, Rasha Mahmoud Gouda, Fatma Elzhraa Ahmed Diab, Ola Ismail Saleh, Heba Mohamed Galal, Mona Gamal El Din Al Anany, Salwa Samir Abd Elgwad, Marwa Mohsen Hassan, Mohamed Ahmed Mostafa Kamal Ahmed, Ahmed Yousri Elamirhttps://journals.aboutscience.eu/index.php/jcb/article/view/2636Detection of PSMA expression on circulating tumor cells by blood-based liquid biopsy in prostate cancer2024-06-26T11:52:54+00:00Santosh Gupta79santosh@gmail.comLuisa Fernandezluisaefa@hotmail.comDavid Bourdondavid.bourdon@epicsciences.comAnis A Hamida.hamid@unimelb.edu.auAnupama PasamAnu.Pasam@petermac.orgErnest Lamernest.lam@epicsciences.comRick Wenstruprick.wenstrup@epicsciences.comShahneen SandhuShahneen.Sandhu@petermac.org<p class="abstract"><strong>Background:</strong> For patients with mCRPC, PSMA-targeted radioligand treatment has significantly improved the clinical outcome. A blood-based liquid biopsy assay for recognizing PSMA protein expression on circulating tumor cells may be beneficial for better informing therapeutic decision-making and identifying the patients most likely to benefit from PSMA-targeted radioligand therapy.</p> <p class="abstract"><strong>Methods:</strong> Using high-throughput imaging and digital AI pathology algorithms, a four-color immunofluorescence assay has been developed to find PSMA protein expression on CTCs on a glass slide. Cell line cells (LNCaP/PC3s/22Rv1) spiked into healthy donor blood were used to study the precision, specificity, sensitivity, limit of detection, and overall accuracy of the assay. Clinical validation and low-pass whole-genome sequencing were performed in PSMA-PET-positive patients with high-risk mCRPC (N = 24) utilizing 3 mL of blood.</p> <p class="abstract"><strong>Results:</strong> The PSMA CTC IF assay achieved analytical specificity, sensitivity, and overall accuracy above 99% with high precision. In the clinical validation, 76% (16/21) of the cases were PSMA positive with CTC heterogeneity, and 88% (21/24) of the patients contained at least one conventional CTC per milliliter of blood. Thirty-six low-pass-sequenced CTCs from 11 individuals with mCRPC frequently exhibited copy number increases in <em>AR</em> and <em>MYC</em> and losses in <em>RB1, PTEN, TP53</em>, and <em>BRCA2</em> locus.</p> <p class="abstract"><strong>Conclusions:</strong> The analytical validation utilizing Epic Sciences’ liquid biopsy CTC platform demonstrated the potential to detect PSMA protein expression in CTCs from patients with mCRPC. This assay is positioned as an effective research tool to evaluate PSMA expression, heterogeneity, and therapeutic response in many ongoing clinical studies to target tumors that express PSMA.</p>2024-02-21T00:00:00+00:00Copyright (c) 2024 Santosh Gupta, Luisa Fernandez, David Bourdon, Anis A Hamid, Anupama Pasam, Ernest Lam, Rick Wenstrup, Shahneen Sandhu